|
2O8J
Human euchromatic histone methyltransferase 2
Deposited 2006-12-12
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain A
913–1193(281 aa)
Fragment:residues 913-1193
|
Not recorded
|
ZN ZINC ION × 4
SAH S-ADENOSYL-L-HOMOCYSTEINE × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 6.5;300 K;peg 3350, pH 6.5, VAPOR DIFFUSION, HANGING DROP, temperature 300K
|
Resolution 1.80 Å
R-free 0.221
|
|
2O8J
Human euchromatic histone methyltransferase 2
Deposited 2006-12-12
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain B
913–1193(281 aa)
Fragment:residues 913-1193
|
Not recorded
|
ZN ZINC ION × 4
SAH S-ADENOSYL-L-HOMOCYSTEINE × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 6.5;300 K;peg 3350, pH 6.5, VAPOR DIFFUSION, HANGING DROP, temperature 300K
|
Resolution 1.80 Å
R-free 0.221
|
|
2O8J
Human euchromatic histone methyltransferase 2
Deposited 2006-12-12
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 3
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain C
913–1193(281 aa)
Fragment:residues 913-1193
|
Not recorded
|
ZN ZINC ION × 4
SAH S-ADENOSYL-L-HOMOCYSTEINE × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 6.5;300 K;peg 3350, pH 6.5, VAPOR DIFFUSION, HANGING DROP, temperature 300K
|
Resolution 1.80 Å
R-free 0.221
|
|
2O8J
Human euchromatic histone methyltransferase 2
Deposited 2006-12-12
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 4
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain D
913–1193(281 aa)
Fragment:residues 913-1193
|
Not recorded
|
ZN ZINC ION × 4
SAH S-ADENOSYL-L-HOMOCYSTEINE × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 6.5;300 K;peg 3350, pH 6.5, VAPOR DIFFUSION, HANGING DROP, temperature 300K
|
Resolution 1.80 Å
R-free 0.221
|
|
3K5K
Discovery of a 2,4-Diamino-7-aminoalkoxy-quinazoline as a Potent Inhibitor of Histone Lysine Methyltransferase, G9a
Deposited 2009-10-07
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain A
913–1193(281 aa)
Fragment:UNP residues 913-1193, SET domain
|
Not recorded
|
ZN ZINC ION × 4
SAH S-ADENOSYL-L-HOMOCYSTEINE × 1
DXQ 7-[3-(dimethylamino)propoxy]-6-methoxy-2-(4-methyl-1,4-diazepan-1-yl)-N-(1-methylpiperidin-4-yl)quinazolin-4-amine × 1
CL CHLORIDE ION × 2
UNX UNKNOWN LIGAND × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 6;293 K;0.2M sodium fluoride, 0.1M Bis-Tris phosphate pH 6.0, 18% polyethylene glycol 3350 and 10% ethylene glycol, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 1.70 Å
R-free 0.264
|
|
3K5K
Discovery of a 2,4-Diamino-7-aminoalkoxy-quinazoline as a Potent Inhibitor of Histone Lysine Methyltransferase, G9a
Deposited 2009-10-07
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain B
913–1193(281 aa)
Fragment:UNP residues 913-1193, SET domain
|
Not recorded
|
ZN ZINC ION × 4
SAH S-ADENOSYL-L-HOMOCYSTEINE × 1
DXQ 7-[3-(dimethylamino)propoxy]-6-methoxy-2-(4-methyl-1,4-diazepan-1-yl)-N-(1-methylpiperidin-4-yl)quinazolin-4-amine × 1
CL CHLORIDE ION × 2
UNX UNKNOWN LIGAND × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 6;293 K;0.2M sodium fluoride, 0.1M Bis-Tris phosphate pH 6.0, 18% polyethylene glycol 3350 and 10% ethylene glycol, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 1.70 Å
R-free 0.264
|
|
3K5K
Discovery of a 2,4-Diamino-7-aminoalkoxy-quinazoline as a Potent Inhibitor of Histone Lysine Methyltransferase, G9a
Deposited 2009-10-07
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 3
Protein homooligomer
Homooligomer;Protein × 2
PDB declaration: dimeric
|
Chain A
913–1193(281 aa)
Fragment:UNP residues 913-1193, SET domain
Chain B
913–1193(281 aa)
Fragment:UNP residues 913-1193, SET domain
|
Not recorded
|
ZN ZINC ION × 8
SAH S-ADENOSYL-L-HOMOCYSTEINE × 2
DXQ 7-[3-(dimethylamino)propoxy]-6-methoxy-2-(4-methyl-1,4-diazepan-1-yl)-N-(1-methylpiperidin-4-yl)quinazolin-4-amine × 2
CL CHLORIDE ION × 4
UNX UNKNOWN LIGAND × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 6;293 K;0.2M sodium fluoride, 0.1M Bis-Tris phosphate pH 6.0, 18% polyethylene glycol 3350 and 10% ethylene glycol, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 1.70 Å
R-free 0.264
|
|
3RJW
Crystal structure of histone lysine methyltransferase g9a with an inhibitor
Deposited 2011-04-15
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer;Protein × 2
PDB declaration: dimeric
|
Chain A
913–1193(281 aa)
Fragment:Sequence database residues 913-1193
Chain B
913–1193(281 aa)
Fragment:Sequence database residues 913-1193
|
Not recorded
|
ZN ZINC ION × 8
SAH S-ADENOSYL-L-HOMOCYSTEINE × 2
CIQ 2-cyclohexyl-6-methoxy-N-[1-(1-methylethyl)piperidin-4-yl]-7-(3-pyrrolidin-1-ylpropoxy)quinazolin-4-amine × 2
UNX UNKNOWN LIGAND × 29
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION;pH 6.5;291 K;0.2M SODIUM FORMATE, 10% ETHYLENE GLYCOL, 25% PEG-3350, 0.1M BIS-TRIS PROPANE, pH 6.5, vapor diffusion, temperature 291K
|
Resolution 2.56 Å
R-free 0.245
|
|
4NVQ
Human G9a in Complex with Inhibitor A-366
Deposited 2013-12-05
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer;Protein × 2
PDB declaration: dimeric
|
Chain A
913–1193(281 aa)
Chain B
913–1193(281 aa)
|
Not recorded
|
2OD 5'-methoxy-6'-[3-(pyrrolidin-1-yl)propoxy]spiro[cyclobutane-1,3'-indol]-2'-amine × 2
SAH S-ADENOSYL-L-HOMOCYSTEINE × 2
ZN ZINC ION × 8
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 5.75;277 K;0.1 M BIS-TRIS, 17.0% PEG3350, pH 5.75, VAPOR DIFFUSION, SITTING DROP, temperature 277K
|
Resolution 2.03 Å
R-free 0.239
|
|
5JHN
Structure of G9a SET-domain with Histone H3K9Ala mutant peptide and bound S-adenosylmethionine
Deposited 2016-04-21
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 4
PDB declaration: tetrameric
|
Chain A
882–1155(274 aa)
Fragment:UNP residues 882-1155
Chain B
882–1155(274 aa)
Fragment:UNP residues 882-1155
|
Not recorded
|
ZN ZINC ION × 8
SAM S-ADENOSYLMETHIONINE × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION;pH 7;298 K;0.2 M Tri-ammonium citrate pH 7 and 20% w/v polyethylene glycol 3350
|
Resolution 1.67 Å
R-free 0.237
|
|
5JIN
Structure of G9a SET-domain with Histone H3K9M mutant peptide and bound S-adenosylmethionine
Deposited 2016-04-22
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 4
PDB declaration: tetrameric
|
Chain A
882–1155(274 aa)
Fragment:UNP residues 882-1155
Chain B
882–1155(274 aa)
Fragment:UNP residues 882-1155
|
Not recorded
|
ZN ZINC ION × 8
SAM S-ADENOSYLMETHIONINE × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION;pH 7;298 K;0.2 M Tri-ammonium citrate pH 7 and 20% w/v polyethylene glycol 3350
|
Resolution 1.85 Å
R-free 0.240
|
|
5JIY
Structure of G9a SET-domain with Histone H3K9norLeucine mutant peptide and bound S-adenosylmethionine
Deposited 2016-04-22
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 4
PDB declaration: tetrameric
|
Chain A
882–1155(274 aa)
Fragment:UNP residues 882-1155
Chain B
882–1155(274 aa)
Fragment:UNP residues 882-1155
|
Not recorded
|
ZN ZINC ION × 8
SAM S-ADENOSYLMETHIONINE × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 7;298 K;0.2 M Tri-ammonium citrate pH 7 and 20% w/v polyethylene glycol 3350
|
Resolution 1.48 Å
R-free 0.233
|
|
5JJ0
Structure of G9a SET-domain with Histone H3K9M peptide and excess SAH
Deposited 2016-04-22
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 4
PDB declaration: tetrameric
|
Chain A
882–1155(274 aa)
Fragment:SET domain of Histone-lysine N-methyltransferase EHMT2 G9a, UNP residues 882-1155
Chain B
882–1155(274 aa)
Fragment:SET domain of Histone-lysine N-methyltransferase EHMT2 G9a, UNP residues 882-1155
|
Not recorded
|
ZN ZINC ION × 8
SAM S-ADENOSYLMETHIONINE × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 7;298 K;0.2 M Tri-ammonium citrate pH 7 and 20% w/v polyethylene glycol 3350
|
Resolution 1.72 Å
R-free 0.252
|
|
5T0K
Structure of G9a SET-domain with H3K9M mutant peptide and SAM
Deposited 2016-08-16
|
Different construct
Different mutation/modification
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain A
879–1159(281 aa)
|
Not recorded
|
ZN ZINC ION × 4
SAM S-ADENOSYLMETHIONINE × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 7.5;293.15 K;0.1 M Bis-Tris propane (pH 7.5), 18% (w/v) PEG3350, 0.2 M NaF, and 5% (v/v) ethylene glycol
|
Resolution 1.70 Å
R-free 0.193
|
|
5T0K
Structure of G9a SET-domain with H3K9M mutant peptide and SAM
Deposited 2016-08-16
|
Different construct
Different mutation/modification
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain B
879–1159(281 aa)
|
Not recorded
|
ZN ZINC ION × 4
SAM S-ADENOSYLMETHIONINE × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 7.5;293.15 K;0.1 M Bis-Tris propane (pH 7.5), 18% (w/v) PEG3350, 0.2 M NaF, and 5% (v/v) ethylene glycol
|
Resolution 1.70 Å
R-free 0.193
|
|
5T0M
A histone H3K9M mutation traps histone methyltransferase Clr4 to prevent heterochromatin spreading
Deposited 2016-08-16
|
Different construct
Different mutation/modification
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain A
879–1159(281 aa)
Fragment:unp residues 879-1159
|
Not recorded
|
ZN ZINC ION × 4
SAM S-ADENOSYLMETHIONINE × 1
SAH S-ADENOSYL-L-HOMOCYSTEINE × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;293.15 K;0.1 M Bis-Tris propane (pH 7.5), 18% (w/v) PEG3350, 0.2 M NaF, and 5% (v/v) ethylene glycol
|
Resolution 1.90 Å
R-free 0.224
|
|
5T0M
A histone H3K9M mutation traps histone methyltransferase Clr4 to prevent heterochromatin spreading
Deposited 2016-08-16
|
Different construct
Different mutation/modification
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain B
879–1159(281 aa)
Fragment:unp residues 879-1159
|
Not recorded
|
ZN ZINC ION × 4
SAM S-ADENOSYLMETHIONINE × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;293.15 K;0.1 M Bis-Tris propane (pH 7.5), 18% (w/v) PEG3350, 0.2 M NaF, and 5% (v/v) ethylene glycol
|
Resolution 1.90 Å
R-free 0.224
|
|
5TTF
Crystal structure of catalytic domain of G9a with MS012
Deposited 2016-11-03
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer;Protein × 2
PDB declaration: dimeric
|
Chain A
879–1159(281 aa)
Fragment:UNP residues 879-1159
Chain C
879–1159(281 aa)
Fragment:UNP residues 879-1159
|
Not recorded
|
ZN ZINC ION × 8
SAM S-ADENOSYLMETHIONINE × 2
7KZ N4-(1-methylpiperidin-4-yl)-N2-hexyl-6,7-dimethoxyquinazoline-2,4-diamine × 2
CL CHLORIDE ION × 1
UNX UNKNOWN LIGAND × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 6.5;291 K;25% PEG 3350, 0.2 M NaCl, 0.1 M Bis-Tris pH6.5
|
Resolution 1.72 Å
R-free 0.247
|
|
5TTF
Crystal structure of catalytic domain of G9a with MS012
Deposited 2016-11-03
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein homooligomer
Homooligomer;Protein × 2
PDB declaration: dimeric
|
Chain B
879–1159(281 aa)
Fragment:UNP residues 879-1159
Chain D
879–1159(281 aa)
Fragment:UNP residues 879-1159
|
Not recorded
|
ZN ZINC ION × 8
SAM S-ADENOSYLMETHIONINE × 2
7KZ N4-(1-methylpiperidin-4-yl)-N2-hexyl-6,7-dimethoxyquinazoline-2,4-diamine × 2
UNX UNKNOWN LIGAND × 3
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 6.5;291 K;25% PEG 3350, 0.2 M NaCl, 0.1 M Bis-Tris pH6.5
|
Resolution 1.72 Å
R-free 0.247
|
|
5TUY
Structure of human G9a SET-domain (EHMT2) in complex with inhibitor MS0124
Deposited 2016-11-07
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer;Protein × 2
PDB declaration: dimeric
|
Chain A
887–1154(268 aa)
Fragment:UNP residues 887-1154
Chain B
887–1154(268 aa)
Fragment:UNP residues 887-1154
|
Not recorded
|
ZN ZINC ION × 8
SAM S-ADENOSYLMETHIONINE × 2
7L6 6,7-dimethoxy-N-(1-methylpiperidin-4-yl)-2-(morpholin-4-yl)quinazolin-4-amine × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION;pH 6.5;290 K;20% (w/v) PEG 3,350, 0.2 M NaF, 0.1 M Bis-Tris propane (pH 6.5)
|
Resolution 2.60 Å
R-free 0.234
|
|
5V9I
Crystal structure of catalytic domain of G9a with MS0105
Deposited 2017-03-23
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer;Protein × 2
PDB declaration: dimeric
|
Chain A
913–1193(281 aa)
Fragment:residues 913-1193
Chain B
913–1193(281 aa)
Fragment:residues 913-1193
|
Not recorded
|
ZN ZINC ION × 8
SAM S-ADENOSYLMETHIONINE × 2
90P N~2~-cyclohexyl-N~4~-(1-ethylpiperidin-4-yl)-6,7-dimethoxy-N~2~-methylquinazoline-2,4-diamine × 2
GOL GLYCEROL × 6
UNX UNKNOWN LIGAND × 3
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 6.5;291 K;25% PEG 3350, 0.2 M NaCl, 0.1 M Bis-Tris pH6.5
|
Resolution 1.74 Å
R-free 0.275
|
|
5V9I
Crystal structure of catalytic domain of G9a with MS0105
Deposited 2017-03-23
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein homooligomer
Homooligomer;Protein × 2
PDB declaration: dimeric
|
Chain C
913–1193(281 aa)
Fragment:residues 913-1193
Chain D
913–1193(281 aa)
Fragment:residues 913-1193
|
Not recorded
|
ZN ZINC ION × 8
SAM S-ADENOSYLMETHIONINE × 2
90P N~2~-cyclohexyl-N~4~-(1-ethylpiperidin-4-yl)-6,7-dimethoxy-N~2~-methylquinazoline-2,4-diamine × 2
GOL GLYCEROL × 3
UNX UNKNOWN LIGAND × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 6.5;291 K;25% PEG 3350, 0.2 M NaCl, 0.1 M Bis-Tris pH6.5
|
Resolution 1.74 Å
R-free 0.275
|
|
5VSC
Structure of human G9a SET-domain (EHMT2) in complex with inhibitor 13
Deposited 2017-05-11
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer;Protein × 2
PDB declaration: dimeric
|
Chain A
916–1190(275 aa)
Fragment:G9a catalytic SET-domain residues 916-1190
Chain B
916–1190(275 aa)
Fragment:G9a catalytic SET-domain residues 916-1190
|
Not recorded
|
ZN ZINC ION × 8
SAM S-ADENOSYLMETHIONINE × 2
9HJ 6,7-dimethoxy-N~2~-methyl-N~4~-(1-methylpiperidin-4-yl)-N~2~-propylquinazoline-2,4-diamine × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION;pH 7.5;290 K;20 % PEG3350, 10% glycerol, 0.2 M Sodium bromide
|
Resolution 1.40 Å
R-free 0.182
|
|
5VSE
Structure of human G9a SET-domain (EHMT2) in complex with inhibitor 17: N~2~-cyclopentyl-6,7-dimethoxy-N~2~-methyl-N~4~-(1-methylpiperidin-4-yl)quinazoline-2,4-diamine
Deposited 2017-05-11
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain A
883–1156(274 aa)
Fragment:G9a catalytic SET-domain (913-1193)
|
Not recorded
|
ZN ZINC ION × 4
SAM S-ADENOSYLMETHIONINE × 1
9HG N~2~-cyclopentyl-6,7-dimethoxy-N~2~-methyl-N~4~-(1-methylpiperidin-4-yl)quinazoline-2,4-diamine × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION;pH 6.5;290 K;20 % PEG3350, 10% glycerol, 0.2 M Sodium fluoride, Bis-Tris propane pH6.5
|
Resolution 1.60 Å
R-free 0.191
|
|
5VSE
Structure of human G9a SET-domain (EHMT2) in complex with inhibitor 17: N~2~-cyclopentyl-6,7-dimethoxy-N~2~-methyl-N~4~-(1-methylpiperidin-4-yl)quinazoline-2,4-diamine
Deposited 2017-05-11
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain B
883–1156(274 aa)
Fragment:G9a catalytic SET-domain (913-1193)
|
Not recorded
|
ZN ZINC ION × 4
SAM S-ADENOSYLMETHIONINE × 1
9HG N~2~-cyclopentyl-6,7-dimethoxy-N~2~-methyl-N~4~-(1-methylpiperidin-4-yl)quinazoline-2,4-diamine × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION;pH 6.5;290 K;20 % PEG3350, 10% glycerol, 0.2 M Sodium fluoride, Bis-Tris propane pH6.5
|
Resolution 1.60 Å
R-free 0.191
|
|
5VSE
Structure of human G9a SET-domain (EHMT2) in complex with inhibitor 17: N~2~-cyclopentyl-6,7-dimethoxy-N~2~-methyl-N~4~-(1-methylpiperidin-4-yl)quinazoline-2,4-diamine
Deposited 2017-05-11
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 3
Protein homooligomer
Homooligomer;Protein × 2
PDB declaration: dimeric
|
Chain A
883–1156(274 aa)
Fragment:G9a catalytic SET-domain (913-1193)
Chain B
883–1156(274 aa)
Fragment:G9a catalytic SET-domain (913-1193)
|
Not recorded
|
ZN ZINC ION × 8
SAM S-ADENOSYLMETHIONINE × 2
9HG N~2~-cyclopentyl-6,7-dimethoxy-N~2~-methyl-N~4~-(1-methylpiperidin-4-yl)quinazoline-2,4-diamine × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION;pH 6.5;290 K;20 % PEG3350, 10% glycerol, 0.2 M Sodium fluoride, Bis-Tris propane pH6.5
|
Resolution 1.60 Å
R-free 0.191
|
|
6MM1
Structure of the cysteine-rich region from human EHMT2
Deposited 2018-09-28
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain A
419–552(134 aa)
Fragment:residues 419-552
|
Not recorded
|
ZN ZINC ION × 4
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;277 K;0.2M potassium sodium tartrate
18% PEG 3350
0.1M HEPES, pH 8.0
|
Resolution 1.90 Å
R-free 0.223
|
|
6MM1
Structure of the cysteine-rich region from human EHMT2
Deposited 2018-09-28
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain B
419–552(134 aa)
Fragment:residues 419-552
|
Not recorded
|
ZN ZINC ION × 4
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;277 K;0.2M potassium sodium tartrate
18% PEG 3350
0.1M HEPES, pH 8.0
|
Resolution 1.90 Å
R-free 0.223
|
|
6MM1
Structure of the cysteine-rich region from human EHMT2
Deposited 2018-09-28
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 3
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain C
419–552(134 aa)
Fragment:residues 419-552
|
Not recorded
|
ZN ZINC ION × 4
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;277 K;0.2M potassium sodium tartrate
18% PEG 3350
0.1M HEPES, pH 8.0
|
Resolution 1.90 Å
R-free 0.223
|
|
6MM1
Structure of the cysteine-rich region from human EHMT2
Deposited 2018-09-28
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 4
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain D
419–552(134 aa)
Fragment:residues 419-552
|
Not recorded
|
ZN ZINC ION × 4
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;277 K;0.2M potassium sodium tartrate
18% PEG 3350
0.1M HEPES, pH 8.0
|
Resolution 1.90 Å
R-free 0.223
|
|
7BTV
Crystal structure of EHMT2 SET domain in complex with compound 5.
Deposited 2020-04-03
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer;Protein × 2
PDB declaration: dimeric
|
Chain A
913–1193(281 aa)
Chain B
913–1193(281 aa)
|
Not recorded
|
ZN ZINC ION × 8
SAM S-ADENOSYLMETHIONINE × 2
N47 N~2~-{4-methoxy-3-[3-(pyrrolidin-1-yl)propoxy]phenyl}-N~4~,6-dimethylpyrimidine-2,4-diamine × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;293 K;0.2 M ammonium acetate, 20% PEG 3350
|
Resolution 2.00 Å
R-free 0.245
|
|
7BUC
Crystal structure of EHMT2 SET domain in complex with compound 13
Deposited 2020-04-06
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer;Protein × 2
PDB declaration: dimeric
|
Chain A
913–1193(281 aa)
Chain B
913–1193(281 aa)
|
Not recorded
|
ZN ZINC ION × 8
SAM S-ADENOSYLMETHIONINE × 2
F80 N2-[4-methoxy-3-(2,3,4,7-tetrahydro-1H-azepin-5-yl)phenyl]-N4,6-dimethyl-pyrimidine-2,4-diamine × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;293 K;0.2 M magnesium acetate, 20% polyethyleneglycol 3350
|
Resolution 2.60 Å
R-free 0.262
|
|
7DCF
Crystal structure of EHMT2 SET domain in complex with compound 10
Deposited 2020-10-26
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer;Protein × 2
PDB declaration: dimeric
|
Chain A
913–1193(281 aa)
Chain B
913–1193(281 aa)
|
Not recorded
|
ZN ZINC ION × 8
SAM S-ADENOSYLMETHIONINE × 2
H30 5'-methoxy-6'-(1-methyl-2,3,4,7-tetrahydroazepin-5-yl)spiro[cyclobutane-1,3'-indole]-2'-amine × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 7;293 K;0.2M NaOAc, pH 7, 20% PEG 3350
|
Resolution 1.80 Å
R-free 0.246
|
|
7T7L
Structure of human G9a SET-domain (EHMT2) in complex with covalent inhibitor (Compound 1)
Deposited 2021-12-15
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer;Protein × 2
PDB declaration: dimeric
|
Chain A
913–1193(281 aa)
Fragment:residues 913-1193
Chain C
913–1193(281 aa)
Fragment:residues 913-1193
|
Not recorded
|
ZN ZINC ION × 8
SAM S-ADENOSYLMETHIONINE × 2
G5U N-(6-methoxy-4-{[1-(propan-2-yl)piperidin-4-yl]amino}-7-[3-(pyrrolidin-1-yl)propoxy]quinazolin-2-yl)propanamide × 1
G4R N-(6-methoxy-4-{[1-(propan-2-yl)piperidin-4-yl]amino}-7-[3-(pyrrolidin-1-yl)propoxy]quinazolin-2-yl)prop-2-enamide × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;290.15 K;2% v/v 1,4-Dioxane, 10% w/v Polyethylene glycol 20,000
|
Resolution 2.20 Å
R-free 0.251
|
|
7T7L
Structure of human G9a SET-domain (EHMT2) in complex with covalent inhibitor (Compound 1)
Deposited 2021-12-15
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein homooligomer
Homooligomer;Protein × 2
PDB declaration: dimeric
|
Chain B
913–1193(281 aa)
Fragment:residues 913-1193
Chain D
913–1193(281 aa)
Fragment:residues 913-1193
|
Not recorded
|
ZN ZINC ION × 8
SAM S-ADENOSYLMETHIONINE × 2
G5U N-(6-methoxy-4-{[1-(propan-2-yl)piperidin-4-yl]amino}-7-[3-(pyrrolidin-1-yl)propoxy]quinazolin-2-yl)propanamide × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;290.15 K;2% v/v 1,4-Dioxane, 10% w/v Polyethylene glycol 20,000
|
Resolution 2.20 Å
R-free 0.251
|
|
7X73
Structure of G9a in complex with RK-701
Deposited 2022-03-09
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer;Protein × 2
PDB declaration: dimeric
|
Chain A
913–1193(281 aa)
Chain B
913–1193(281 aa)
|
Not recorded
|
ZN ZINC ION × 8
SFG SINEFUNGIN × 2
J26 N-[(2S)-1-[(4-cyanophenyl)amino]-4-cyclopropyl-1-oxidanylidene-butan-2-yl]-3,6,6-trimethyl-4-oxidanylidene-5,7-dihydro-1H-indole-2-carboxamide × 2
EDO 1,2-ETHANEDIOL × 3
TRS 2-AMINO-2-HYDROXYMETHYL-PROPANE-1,3-DIOL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 7.4;293 K;0.1M Bis-Tris propane (pH 7.4), 0.2M sodium formate, 10% ethylene glycol, 25% PEG3350
|
Resolution 1.49 Å
R-free 0.193
|
|
7XUA
Structure of G9a in complex with compound 10a
Deposited 2022-05-18
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer;Protein × 2
PDB declaration: dimeric
|
Chain A
913–1193(281 aa)
Chain B
913–1193(281 aa)
|
Not recorded
|
ZN ZINC ION × 8
SFG SINEFUNGIN × 2
I5X ~{N}-[(1~{S})-1-(1~{H}-benzimidazol-2-yl)-3-methylsulfanyl-propyl]-3,6,6-trimethyl-4-oxidanylidene-5,7-dihydro-1~{H}-indole-2-carboxamide × 2
TRS 2-AMINO-2-HYDROXYMETHYL-PROPANE-1,3-DIOL × 1
EDO 1,2-ETHANEDIOL × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;293 K;0.1M Bis-Tris propane (pH7.5), 0.2M Sodium Formate, 10% Ethylene Glycol, 23.5% PEG3350
|
Resolution 1.87 Å
R-free 0.224
|
|
7XUB
Structure of G9a in complex with compound 10d
Deposited 2022-05-18
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer;Protein × 2
PDB declaration: dimeric
|
Chain A
913–1193(281 aa)
Chain B
913–1193(281 aa)
|
Not recorded
|
ZN ZINC ION × 8
SFG SINEFUNGIN × 2
I6L ~{N}-[(1~{S})-1-(1~{H}-benzimidazol-2-yl)pentyl]-3,6,6-trimethyl-4-oxidanylidene-5,7-dihydro-1~{H}-indole-2-carboxamide × 2
EDO 1,2-ETHANEDIOL × 3
TRS 2-AMINO-2-HYDROXYMETHYL-PROPANE-1,3-DIOL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;293 K;0.1M Bis-Tris propane (7.75), 0.2M Sodium Formate, 10% Ethylene Glycol, 26% PEG3350
|
Resolution 2.00 Å
R-free 0.215
|
|
7XUC
Structure of G9a in complex with compound 11a
Deposited 2022-05-18
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer;Protein × 2
PDB declaration: dimeric
|
Chain A
913–1193(281 aa)
Chain B
913–1193(281 aa)
|
Not recorded
|
ZN ZINC ION × 8
SFG SINEFUNGIN × 2
I6S 3,6,6-trimethyl-4-oxidanylidene-~{N}-[(2~{S})-1-oxidanylidene-1-phenylazanyl-hexan-2-yl]-5,7-dihydro-1~{H}-indole-2-carboxamide × 2
EDO 1,2-ETHANEDIOL × 3
CL CHLORIDE ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;293 K;0.1M Bis-Tris propane (pH7.5), 0.2M Sodium Fluoride, 10% Ethylene Glycol, 25% PEG3350
|
Resolution 1.67 Å
R-free 0.186
|
|
7XUD
Structure of G9a in complex with compound 26a
Deposited 2022-05-18
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer;Protein × 2
PDB declaration: dimeric
|
Chain A
913–1193(281 aa)
Chain B
913–1193(281 aa)
|
Not recorded
|
ZN ZINC ION × 8
CL CHLORIDE ION × 1
SFG SINEFUNGIN × 2
I6Z ~{N}-[(2~{S})-4-cyclopropyl-1-oxidanylidene-1-phenylazanyl-butan-2-yl]-3,6,6-trimethyl-4-oxidanylidene-5,7-dihydro-1~{H}-indole-2-carboxamide × 2
EDO 1,2-ETHANEDIOL × 3
TRS 2-AMINO-2-HYDROXYMETHYL-PROPANE-1,3-DIOL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;293 K;0.1M Bis-Tris propane (pH7.5), 0.2M Sodium Fluoride, 10% Ethylene Glycol, 22% PEG3350
|
Resolution 1.45 Å
R-free 0.177
|
|
8VV8
Crystal Structure of EHMT2 bound to EZM8266
Deposited 2024-01-30
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain A
913–1193(281 aa)
Fragment:residues 913-1193
|
Not recorded
|
SAM S-ADENOSYLMETHIONINE × 1
A1AEB (2R)-1-(azetidin-1-yl)-3-(2-methoxy-5-{[4-methyl-6-(methylamino)pyrimidin-2-yl]amino}phenoxy)propan-2-ol × 1
ZN ZINC ION × 4
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;277 K;0.2 M Potassium fluoride, 20 %(w/v) PEG 3350
|
Resolution 2.00 Å
R-free 0.247
|
|
8VV8
Crystal Structure of EHMT2 bound to EZM8266
Deposited 2024-01-30
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain B
913–1193(281 aa)
Fragment:residues 913-1193
|
Not recorded
|
SAM S-ADENOSYLMETHIONINE × 1
A1AEB (2R)-1-(azetidin-1-yl)-3-(2-methoxy-5-{[4-methyl-6-(methylamino)pyrimidin-2-yl]amino}phenoxy)propan-2-ol × 1
ZN ZINC ION × 4
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;277 K;0.2 M Potassium fluoride, 20 %(w/v) PEG 3350
|
Resolution 2.00 Å
R-free 0.247
|
|
8Z7C
Structure of G9a in complex with compound 7i
Deposited 2024-04-20
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer;Protein × 2
PDB declaration: dimeric
|
Chain A
913–1193(281 aa)
Chain B
913–1193(281 aa)
|
Not recorded
|
ZN ZINC ION × 8
SFG SINEFUNGIN × 2
A1L07 3,6,6-trimethyl-~{N}-[(2~{S})-1-[[4-(1-methylpiperidin-4-yl)oxyphenyl]amino]-1-oxidanylidene-hexan-2-yl]-4-oxidanylidene-5,7-dihydro-1~{H}-indole-2-carboxamide × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;293 K;0.1M Bis-Tris propane (pH~7.5), 0.2M Sodium Formate or Fluoride, 10% Ethylene Glycol, ~25% PEG3350
|
Resolution 1.52 Å
R-free 0.196
|
|
8Z7D
Structure of G9a in complex with compound 9a
Deposited 2024-04-20
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer;Protein × 2
PDB declaration: dimeric
|
Chain A
913–1193(281 aa)
Chain B
913–1193(281 aa)
|
Not recorded
|
ZN ZINC ION × 8
SFG SINEFUNGIN × 2
A1L08 3,6,6-trimethyl-4-oxidanylidene-~{N}-[(2~{S})-1-oxidanylidene-1-[(phenylmethyl)amino]hexan-2-yl]-5,7-dihydro-1~{H}-indole-2-carboxamide × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;293 K;0.1M Bis-Tris propane (pH~7.5), 0.2M Sodium Formate or Fluoride, 10% Ethylene Glycol, ~25% PEG3350
|
Resolution 1.58 Å
R-free 0.183
|
|
8Z7E
Structure of G9a in complex with compound 9b
Deposited 2024-04-20
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer;Protein × 2
PDB declaration: dimeric
|
Chain A
913–1193(281 aa)
Chain B
913–1193(281 aa)
|
Not recorded
|
ZN ZINC ION × 8
SFG SINEFUNGIN × 2
A1L09 ~{N}-[(2~{S})-1-[[4-[(dimethylamino)methyl]phenyl]methylamino]-1-oxidanylidene-hexan-2-yl]-3,6,6-trimethyl-4-oxidanylidene-5,7-dihydro-1~{H}-indole-2-carboxamide × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;293 K;0.1M Bis-Tris propane (pH~7.5), 0.2M Sodium Formate or Fluoride, 10% Ethylene Glycol, ~25% PEG3350
|
Resolution 1.54 Å
R-free 0.195
|
|
9KLB
G9a in complex with RK-133232 (compound 16g)
Deposited 2024-11-14
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer;Protein × 2
PDB declaration: dimeric
|
Chain A
913–1193(281 aa)
Chain B
913–1193(281 aa)
|
Not recorded
|
ZN ZINC ION × 8
SFG SINEFUNGIN × 2
A1L57 ~{N}-[(~{E},2~{S})-4-cyclopropyl-1-[(6-ethoxypyridin-3-yl)amino]-1-oxidanylidene-but-3-en-2-yl]-4-(pyridin-4-ylamino)benzamide × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;293 K;0.1M Bis-Tris propane (pH~7.5), 0.2M Sodium Formate or Fluoride, 10% Ethylene Glycol, ~25% PEG3350
|
Resolution 1.81 Å
R-free 0.221
|
|
9KLC
G9a in complex with the S-isomer of RK-131902 (racemic compound rac-10a)
Deposited 2024-11-14
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer;Protein × 2
PDB declaration: dimeric
|
Chain A
913–1193(281 aa)
Chain B
913–1193(281 aa)
|
Not recorded
|
ZN ZINC ION × 8
SFG SINEFUNGIN × 2
A1L58 ~{N}-[(2~{S})-1-[[6-(1-methylpiperidin-4-yl)oxypyridin-3-yl]amino]-1-oxidanylidene-hexan-2-yl]-3-(pyridin-4-ylamino)benzamide × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;293 K;0.1M Bis-Tris propane (pH~7.5), 0.2M Sodium Formate or Fluoride, 10% Ethylene Glycol, ~25% PEG3350
|
Resolution 2.15 Å
R-free 0.253
|
|
9LUS
Structure of human G9a SET-domain in complex with FLAV27 inhibitor
Deposited 2025-02-10
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer;Protein × 2
PDB declaration: dimeric
|
Chain A
913–1193(281 aa)
Chain B
913–1193(281 aa)
|
Not recorded
|
ZN ZINC ION × 2
A1L7O 3-[1-[[(2~{S})-4-(phenylmethyl)-1,4-oxazepan-2-yl]methyl]piperidin-4-yl]phenol × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;277.15 K;peg3350 20%, 10% Tacsimate (ph-8), Tris (ph-8.2), Glycerol 6%, 5 mM KSCN
|
Resolution 2.70 Å
R-free 0.309
|
|
9WRI
Crystal structure of CtBP2 in complex with G9a
Deposited 2025-09-12
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 6
PDB declaration: hexameric
|
Chain C
881–893(13 aa)
|
Not recorded
|
NAD NICOTINAMIDE-ADENINE-DINUCLEOTIDE × 4
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 7.5;291 K;0.1 M HEPES pH 7.5, 6% PVP, 30% pentaerythritol ethoxylate
|
Resolution 1.85 Å
R-free 0.202
|
|
9YKS
Crystal structure of the G9a (EHMT2) SET domain in complex with SAM and TNG917
Deposited 2025-10-07
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer;Protein × 2
PDB declaration: dimeric
|
Chain A
912–1193(282 aa)
Fragment:catalytic SET domain (UNP residues 912-1193)
Chain B
912–1193(282 aa)
Fragment:catalytic SET domain (UNP residues 912-1193)
|
Not recorded
|
ZN ZINC ION × 8
SAM S-ADENOSYLMETHIONINE × 2
A1CXM N~2~-[(7M)-6-fluoro-7-(2,5,6,7-tetrahydro-1H-azepin-4-yl)-2,3-dihydro-1-benzofuran-5-yl]-N~4~,6-dimethylpyrimidine-2,4-diamine × 2
EDO 1,2-ETHANEDIOL × 7
GOL GLYCEROL × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 6.5;291 K;33% PEG4000, 200 mM sodium acetate, 100 mM MES, pH 6.5
|
Resolution 1.79 Å
R-free 0.252
|
|
9YKS
Crystal structure of the G9a (EHMT2) SET domain in complex with SAM and TNG917
Deposited 2025-10-07
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein homooligomer
Homooligomer;Protein × 2
PDB declaration: dimeric
|
Chain C
912–1193(282 aa)
Fragment:catalytic SET domain (UNP residues 912-1193)
Chain D
912–1193(282 aa)
Fragment:catalytic SET domain (UNP residues 912-1193)
|
Not recorded
|
ZN ZINC ION × 8
SAM S-ADENOSYLMETHIONINE × 2
A1CXM N~2~-[(7M)-6-fluoro-7-(2,5,6,7-tetrahydro-1H-azepin-4-yl)-2,3-dihydro-1-benzofuran-5-yl]-N~4~,6-dimethylpyrimidine-2,4-diamine × 2
EDO 1,2-ETHANEDIOL × 6
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 6.5;291 K;33% PEG4000, 200 mM sodium acetate, 100 mM MES, pH 6.5
|
Resolution 1.79 Å
R-free 0.252
|